S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

OTCMKTS:GNMSF - Genmab A/S Stock Price, Forecast & News

$194.00
-5.90 (-2.95 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$194.00
Now: $194.00
$213.95
50-Day Range
$159.80
MA: $217.00
$250.15
52-Week Range
$159.45
Now: $194.00
$250.15
Volume79 shs
Average Volume1,270 shs
Market Capitalization$11.97 billion
P/E Ratio38.49
Dividend YieldN/A
Beta0.2
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More
Genmab A/S logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNMSF
CUSIPN/A
CIKN/A
Phone45-7020-2728

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$804.57 million
Cash Flow$5.44 per share
Book Value$34.13 per share

Profitability

Net Income$324.68 million

Miscellaneous

Employees377
Market Cap$11.97 billion
Next Earnings Date5/6/2020 (Confirmed)
OptionableNot Optionable

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.


Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions

How has Genmab A/S's stock been impacted by COVID-19 (Coronavirus)?

Genmab A/S's stock was trading at $211.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNMSF stock has decreased by 8.1% and is now trading at $194.00. View which stocks have been mosted impacted by Coronavirus.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Genmab A/S.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings results on Wednesday, February, 19th. The company reported $3.43 EPS for the quarter. The firm had revenue of $438.89 million for the quarter. Genmab A/S had a return on equity of 19.95% and a net margin of 40.23%. View Genmab A/S's earnings history.

Has Genmab A/S been receiving favorable news coverage?

News headlines about GNMSF stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genmab A/S earned a daily sentiment score of 0.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutGenmab A/S.

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the following people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 58)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)
  • Ms. Jane Juel, Sr. Director of Operations & Resource Management
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $194.00.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $11.97 billion and generates $804.57 million in revenue each year. Genmab A/S employs 377 workers across the globe. View additional information about Genmab A/S.

What is Genmab A/S's official website?

The official website for Genmab A/S is http://www.genmab.com/.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  158 (Thanks for Voting!)
Underperform Votes:  258 (Thanks for Voting!)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel